RA0553

antibody from Oursmab

Targeting: PDCD1 CD279, hSLE1, PD-1, PD1, SLEB2

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0553

Provider

Oursmab

Product name

Acrixolimab (Biosimilar Reference Antibody) (PDCD1)

Antibody type

Monoclonal

Description

Acrixolimab is a monoclonal antibody that has been investigated as an antineoplastic and immunotherapy agent. The drug is classified as a Programmed Cell Death 1 (PD-1) receptor antagonist, placing it in the category of immune checkpoint inhibitors. The proposed mechanism of action involves blocking the PD-1 receptor to release the "brake" on T cell activity, thereby restoring the immune system's ability to attack cancer cells. In addition to direct receptor antagonism, its mechanism is also associated with Antibody-Dependent Cell Cytotoxicity (ADCC), suggesting it may also promote the direct killing of target cells by immune effector cells. Acrixolimab was developed by Y-Biologics and has been studied for various advanced cancers.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.